HOME > Detail View

Detail View

Peptide and protein hormones : structure, regulation, activity :a reference manual

Peptide and protein hormones : structure, regulation, activity :a reference manual (Loan 2 times)

Material type
단행본
Personal Author
Konig, Wolfgang, Dr.
Title Statement
Peptide and protein hormones : structure, regulation, activity :a reference manual / Wolfgang Konig.
Publication, Distribution, etc
Weinheim ;   New York :   VCH,   c1993.  
Physical Medium
xii, 284 p. : ill. ; 25 cm.
ISBN
3527284176 (Weinheim : acid-free, low chlorine paper) 1560812117 (New York : acid-free, low chlorine paper)
Bibliography, Etc. Note
Includes bibliographical references (p. [217]-275) and index.
Subject Added Entry-Topical Term
Peptide hormones. Protein hormones.
000 00858camuuu200241 a 4500
001 000000918385
005 19990125141348.0
008 920618s1993 gw a b 001 0 eng
010 ▼a 92024855
020 ▼a 3527284176 (Weinheim : acid-free, low chlorine paper)
020 ▼a 1560812117 (New York : acid-free, low chlorine paper)
040 ▼a DLC ▼c DLC ▼d DLC ▼d 244002
049 0 ▼l 151028292
050 0 0 ▼a QP572.P4 ▼b K66 1993
082 0 0 ▼a 612.4/05 ▼2 20
090 ▼a 612.405 ▼b K82p
100 1 ▼a Konig, Wolfgang, ▼c Dr.
245 1 0 ▼a Peptide and protein hormones : ▼b structure, regulation, activity :a reference manual / ▼c Wolfgang Konig.
260 ▼a Weinheim ; ▼a New York : ▼b VCH, ▼c c1993.
300 ▼a xii, 284 p. : ▼b ill. ; ▼c 25 cm.
504 ▼a Includes bibliographical references (p. [217]-275) and index.
650 0 ▼a Peptide hormones.
650 0 ▼a Protein hormones.

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Sejong Academic Information Center/Science & Technology/ Call Number 612.405 K82p Accession No. 151028292 Availability Available Due Date Make a Reservation Service C

Contents information

Table of Contents


CONTENTS
1. Introduction = 1
 1.1. Synthesis of Peptide and Protein Hormones = 1
 1.2. Mechanism of Action of Peptide and Protein Hormones = 2
 1.3. Nomenclature and Abbreviations = 3
2. Gonadoliberin, Thyroliberin, Gonadotropins, Thyrotropin = 11
 2.1. Gonadoliberin = 12
  2.1.1. Occurrence = 12
  2.1.2. Release = 12
  2.1.3. Receptors = 13
  2.1.4. Biological Effects = 13
  2.1.5. Structure-Activity Relationships = 14
  2.1.6. Applications = 15
 2.2. Gonadoliberin from Follicle Fluids = 16
 2.3. Thyroliberin = 16
  2.3.1. Occurrence = 16
  2.3.2. Release = 17
  2.3.3. Receptors = 17
  2.3.4. Biological Effects = 17
  2.3.5. Structure-Activity Relationships = 18
  2.3.6. Applications = 19
 2.4. Gonadotropins = 20
  2.4.1. Occurrence = 20
  2.4.2. Release = 20
  2.4.3. Receptors = 24
  2.4.4. Biological Effects = 24
  2.4.5. Structure-Activity Relationships = 25
  2.4.6. Applications = 26
 2.5. Tyrotropin = 26
  2.5.1. Occurrence = 26
  2.5.2. Release = 26
  2.5.3. Receptors = 27
  2.5.4. Biological Effects = 27
  2.5.5. Structure-Activity Relationships = 27
 2.6. Protein 7B2 = 27
 2.7. Inhibins, Activins, and Related Hormones = 28
  2.7.1. Common Structural Characteristics = 28
  2.7.2. Inhibins = 28 
  2.7.3. Activins = 31
  2.7.4. Transforming Growth Factor-β = 32
  2.7.5. Bone Morphogenetic Proteins and Osteogenic Proteins = 34
  2.7.6. Muellerian Inhibiting Substance = 35 
 2.8. Follistatin = 35
  2.8.1. Occurrence = 35
  2.8.2. Biological Effects = 36 
3. Parathyroid Hormone and the Calcitonin Family = 37 
 3.1. Parathyroid Hormone and PTH-Related Protein = 37
  3.1.1. Occurrence = 37
  3.1.2. Release of PTH = 38
  3.1.3. Receptors of PTH = 40 
  3.1.4. Activity of PTH = 40 
  3.1.5. Activity of PTHrP = 41 
  3.1.6. Structure-Activity Relationships = 42 
  3.1.7. PTH Antagonists = 42
  3.1.8. Applications = 42 
 3.2. Calcitonin = 43 
  3.2.1. Occurrence = 43
  3.2.2. Release of CT = 43 
  3.2.3. Receptors = 44
  3.2.4. Biological Effects of CT = 44
  3.2.5. Structure-Activity Relationships = 45
  3.2.6. Applications = 46
 3.3. Calcitonin Gene Related Peptides = 47
  3.3.1. Occurrence = 47
  3.3.2. Release = 47
  3.3.3. Receptors = 47
  3.3.4. Biological Effects = 48
  3.3.5. Structure-Activity Relationships = 49
 3.4. Amylin = 49
4. Corticoliberin-Proopiomelanocortin Cascade = 51
 4.1. Corticoliberin = 54
  4.1.1. Occurrence = 54 
  4.1.2. Release = 55
  4.1,3. Receptors = 56
  4.1.4. Biological Effects = 56
  4.1.5. Structure-Activity Relationships = 58
  4.1.6. Applications = 58
 4.2. Corticotropin = 59
  4.2.1. Occurrence = 59
  4.2.2. Release = 59
  4.2.3. Receptors = 60
  4.2.4. Biological Effects = 60
  4.2.5. Structure-Activity Relationships = 62
  4.2.6. Applications = 63
 4.3. α- , β- , γ- and δ-Melanotropin (MSH) = 63
  4.3.1. Occurrence = 63
  4.3.2. Release = 64
  4.3.3. Biological Effects of α-MSH = 65
  4.3.4. Biological Effects of β-MSH = 66
  4.3.5. Biological Effects of γ-MSH = 66
  4.3.6. Structure-Activity Relationships = 66
  4.3.7. Antagonists = 68
  4.3.8. Applications = 68
 4.4. Melanotropin-Like Peptides from Crustacea and Fish = 69
 4.5. Opioid Peptides = 69
  4.5.1. Introduction = 69
  4.5.2. Opioid Receptors = 70
  4.5.3. Opioid Actions = 72
  4.5.4. β-Endorphin = 74
  4.5.5. Peptides of Preproenkephalins A and B = 77
   4.5.5.1. Peptides Derived from Preproenkephalin A = 77
   4.5.5.2. Peptides Derived from Preproenkephalin B = 80
  4.5.6. Dermorphin and Deltorphins = 82
  4.5.7. Kyotorphin = 84
  4.5.8. Exorphins = 85
  4.5.9. Femarfarmamide and Related Structures = 86
5. Blood Pressure Regulating Peptiees = 89
 5.1. The Angiotensin-Kinin System = 89
  5.1.1. Angiotensins = 90
  5.1.2. Kinins = 94
   5.1.2.1. Occurrence = 94
   5.1.2.2. Release = 96
   5.1.2.3. Receptors = 77
   5.1.2.4. Biological Effects = 97
   5.1.2.5. Structure-Activity Relationships = 98
   5.1.2.6. Applications = 99
 5.2. Substance P, Neurokinins and Tachykinins = 99
  5.2.1. Occurrence = 99
  5.2.2. Release = 80
  5.2.3. Metabolism of SP = 101
  5.2.4. Receptors = 102
  5.2.5, Biological Effects = 104
  5.2.6. Structure-Activity Relationships = 105
  5.2.7. Amyloid A4 Protein = 106
 5.3. Vasopressin, Oxytocin and Vasotocin = 108
  5.3.1. Occurrence = 108
  5.3.2. Release = 108
  5.3.3. Receptors = 110
  5.3.4. Biological Effects of VP = 110
  5.3.5. Biological Effects of OT = 111
  5.3.6. Biological Effects of VT = 111
  5.3.7. Structure-Activity Relationships = 111
  5.3.8. Antagonists = 112
  5.3.9. Applications = 115
  5.3.10. Melanostatin = 115
 5.4. Endothelin = 116
  5.4.1. Occurrence = 116
  5.4.2. Release = 116
  5.4.3. Receptors = 117
  5.4.4. Biological Effects = 117
  5.4.5. Structure-Activity Relationships = 118
 5.5. Atrial Natriuretic Factor = 119
  5.5.1. Occurrence = 119
  5.5.2. Release = 122
  5.5.3. Receptors = 123
  5.5.4. Biological Effects = 124
  5.5.5. Structure-Activity Relationships = 125
  5.5.6. Inhibitors = 126
 5.6. Pancreatic Peptide Family = 127
  5.6.1. Pancreatic Peptide = 127
  5.6.2. Neuropeptide Y = 129
  5.6.3. Peptide with N-terminal Tyrosine and C-terminal Tyrosinamide = 132
  5.6.4. Neuromedin U = 133
  5.6.5. δ-Sleep Inducing Peptide = 133
6. Cholecystokinin and Gastrin = 135.
 6.1. Trypsin Sensitive Cholecystokinin Releasing Peptide = 135
 6.2. Cholecystokinin / Pancreozymin and Caerulein = 136
  6.2.1. Occurrence = 136
  6.2.2. Release = 137
  6.2.3. Receptors = 137
  6.2.4. Biological Effects = 138
  6.2.5. Structure-Activity Relationships = 139
  6.2.6. Antagonists = 140
  6.2.7. Applications = 141
 6.3. Gastrin Releasing Peptide and Bombesin = 141
  6.3.1. Occurrence = 141
  6.3.2. Release = 141
  6.3.3. Receptors = 142
  6.3.4. Biological Effects = 143
  6.3.5. Structure-Activity Relationships = 144
  6.3.6. Antagonists = 144
  6.3.7. Applications = 145
 6.4. Gastrin = 145
  6.4.1. Occurrence = 145
  6.4.2. Release = 146
  6.4.3. Biological Effects = 147
  6.4.4. Structure-Activity Relationships = 148
  6.4.5. Antagonists = 149
  6.4.6. Applications = 149
 6.5. Valosin = 149
7. Secietin Family = 151
 7.1. Secretin = 151
 7.2. Vasoactive Intestinal Peptide and PHI-27 / PHM-27 = 155
 7.3. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) = 158
 7.4. Helodermin and Helospectin = 159
 7.5. Glucagon and Related Peptides = 161
  7.5.1. Glucagon = 161
  7.5.2. Glicentin and Enteroglucagon = 164
  7.5.3. Glucagon Like Peptide-1-(7-36)-amide = 164
  7.5.4. Crustacean Hyperglycemic and Molt Inhibiting Hormone (CHH) = 166
 7.6. Gastrin Inhibiting or Glucose Dependent Insulinotropic Peptide = 167
  7.6.1. Chymodenin = 168
 7.7. Somatoliberin and the Growth Hormone Cascade = 168
  7.7.1. Galanine = 169
  7.7.2. Somatoliberin = 171
   7.7.2.1. SK&F 110679 = 174
  7.7.3. Somatotropin, Placenta Lactogen and Prolactin = 774
   7.7.3.1. Somatotropin = 175
   7.7.3.2. Prolactin = 180
  7.7.3. Placenta Lactogen = 186
  7.7.4. Somatomedins, Insulin and Relaxin = 186
   7.7.4.1. Somatomedins = 186
   7.7.4.2. Somatomedin B = 190
   7.7.4.3. Insulin = 191
    7.7.4.3.1. Pancreastatin = 197
   7.7.4.4. Relaxin = 199
  7.7.5. Somatostatin = 201
8. Neurotensin = 207
 8.1. Occurrence = 207
 8.2. Release = 208
 8.3. Biological Effects = 209
 8.4. Structure-Activity Relationships = 210
9. Motilin = 213
 9.1. Occurrence = 213
 9.2. Release = 213
 9.3. Biological Effects = 213
 9.4. Structure-Activity Relationships = 214
10. Pancreatic Spasmolytic Peptide = 215
 10.1. Occurrence = 215
 10.2. Biological Effects = 215
11. References = 217
Subject Index = 277


New Arrivals Books in Related Fields

Barrett, Lisa Feldman (2021)
Slotnick, Scott (2021)
Schoenwolf, Gary (2021)
VanPutte, Cinnamon L (2021)